RxDoctor Payments Data

Brookellen Rider, DO

Family Medicine · Berlin, MDNPI 1326036617

Payments from drug & device makers

$7,080in general payments, 2019–2025

Across 290 payments — averaging $24.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • AstraZeneca$824
  • GSK$680
  • Pfizer$583
  • AbbVie$494
  • Novo Nordisk$492
  • plus $3K from 34 others

What the payments were for

  • Food & beverage$7,080100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,080 in reported general payments places this provider in the 90th percentile of 1,193 family medicine providers in Maryland.

See all family medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$243,169
Medicare patients
612
Services billed
7,407

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban44$54,600
XareltoRivaroxaban37$45,790
OzempicSemaglutide33$36,289
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$22,111
JardianceEmpagliflozin16$17,538
Breo ElliptaFluticasone/Vilanterol23$15,623
JanuviaSitagliptin Phosphate21$13,522
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr15$10,876
MyrbetriqMirabegron13$8,190
Atorvastatin Calcium464$6,112
SynthroidLevothyroxine Sodium77$5,887
VyvanseLisdexamfetamine Dimesylate15$5,505
Fluticasone-SalmeterolFluticasone Propion/Salmeterol28$5,504
Dexlansoprazole DrDexlansoprazole14$5,280
Rosuvastatin Calcium203$4,986

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$583$54,60044 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$680$48,60964 claims
Novo NordiskOzempic$492$36,28933 claims
Boehringer IngelheimJardiance$252$17,53816 claims
MerckJanuvia$298$13,52221 claims
Astellas Pharma US IncMyrbetriq$34$8,19013 claims
AbbVieSynthroid$494$5,88777 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$15$5,50515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,193 family medicine providers in Maryland.

Other family medicine in Berlin

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →